173 related articles for article (PubMed ID: 3295625)
1. [Primary treatment of hairy cell leukemia with low-dose human recombinant interferon-alpha-2c (Hr-IFn alpha 2c) in comparison with therapy following splenectomy. Interferon (IFn-alpha 2c) in HCL before or after splenectomy].
Pralle H; Zwingers T; Boedewadt S; Bross K; Dörken B; Gamm H; Ho AD; Parwaresch RM; Schmitz N; Papendick U
Onkologie; 1987 Feb; 10(1):5-10. PubMed ID: 3295625
[TBL] [Abstract][Full Text] [Related]
2. [Alpha interferon in the therapy of hairy cell leukemia. Results of 3 prospective multicenter studies in West Germany].
Pralle H; Bartel A; Boedewadt-Radzun S; Bross K; Bruhn HD; Dörken B; Drees N; Essers U; Fuhr H; Gamm H
Onkologie; 1988 Feb; 11(1):44-7. PubMed ID: 3283625
[TBL] [Abstract][Full Text] [Related]
3. A prospective multicenter trial with human recombinant alpha 2c-interferon in hairy cell leukemia before and after splenectomy.
Pralle H; Zwingers T; Boedewadt S; Bross K; Dörken B; Gamm H; Ho AD; Parwaresch RM; Schmitz N; Papendick U
Leukemia; 1987 Apr; 1(4):337-40. PubMed ID: 3669759
[TBL] [Abstract][Full Text] [Related]
4. Splenectomy following complete response to alpha interferon (IFN) therapy in patients with hairy cell leukemia (HCL): results of the HCL88 protocol. Italian Cooperative Group for the Study of Hairy Cell Leukemia (ICGHCL).
Damasio EE; Frassoldati A
Leuk Lymphoma; 1994; 14 Suppl 1():95-8. PubMed ID: 7820061
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients.
Gastl G; Werter M; De Pauw B; Nerl C; Aulitzky W; von Lüttichau I; Tilg H; Thaler J; Lang A; Abbrederis K
Leukemia; 1989 Jun; 3(6):453-60. PubMed ID: 2725061
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL.
Federico M; Frassoldati A; Lamparelli T; Foà R; Brugiatelli M; Annino L; Baldini L; Capnist G; Chisesi T; di Celle PF
Ann Oncol; 1994 Oct; 5(8):725-31. PubMed ID: 7826905
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness of gamma interferon and alpha interferon in hairy cell leukemia].
Niederle N; Doberauer C; Kloke O; Höffken K; Schmidt CG
Klin Wochenschr; 1987 Jul; 65(14):706-12. PubMed ID: 3114551
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interferon-alpha-2b treatment of hairy-cell leukaemia: experience with a low-dose schedule.
Hasselbalch H; Braide I; Lisse I; Röckert LL; Swolin B; Carneskog J; Hagberg H; Hippe E; Jensen MK; Lundin P
Eur J Haematol; 1988 Nov; 41(5):438-44. PubMed ID: 3061836
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b.
Glaspy JA; Souza L; Scates S; Narachi M; Blatt L; Ambersley J; Golde DW
J Immunother (1991); 1992 Apr; 11(3):198-208. PubMed ID: 1381218
[TBL] [Abstract][Full Text] [Related]
10. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
Huber C; Aulitzky W; Tilg H; von Lüttichau I; Troppmair J; Nachbauer K; Gastl G
Leukemia; 1987 Apr; 1(4):355-7. PubMed ID: 3669762
[TBL] [Abstract][Full Text] [Related]
11. Treatment with low dose human recombinant interferon-alpha-2-ARG induces complete remission in patients with hairy cell leukemia.
Gastl G; Denz H; Abbrederis C; Huber H; Troppmair J; Wiegele J; Niederwieser D; Flener R; Huber C
Onkologie; 1985 Jun; 8(3):143-4. PubMed ID: 3895095
[TBL] [Abstract][Full Text] [Related]
12. [Low-dose alpha-interferon treatment of hairy cell leukemia].
von Wussow P; Freund M; Block B; Diedrich H; Schmoll H; Poliwoda H; Deicher H
Klin Wochenschr; 1987 Jul; 65(14):681-4. PubMed ID: 3626433
[TBL] [Abstract][Full Text] [Related]
13. Should alpha interferon be used as primary treatment for hairy cell leukemia? Italian Cooperative Group for Hairy Cell Leukemia.
Capnist G; Federico M; Chisesi T; Resegotti L; Pagnucco G; Castoldi GL; Lamparelli T; Frassoldati A; Guarnaccia C; Leoni P
Leuk Res; 1991; 15(6):419-26. PubMed ID: 1861528
[TBL] [Abstract][Full Text] [Related]
14. The role of interferon in the treatment of hairy cell leukemia.
Ratain MJ; Vardiman JW; Golomb HM
Semin Oncol; 1986 Sep; 13(3 Suppl 2):21-8. PubMed ID: 3532332
[TBL] [Abstract][Full Text] [Related]
15. Durability of responses to interferon alfa-2b in advanced hairy cell leukemia.
Ratain MJ; Golomb HM; Bardawil RG; Vardiman JW; Westbrook CA; Kaminer LS; Lembersky BC; Bitter MA; Daly K
Blood; 1987 Mar; 69(3):872-7. PubMed ID: 3814819
[TBL] [Abstract][Full Text] [Related]
16. Splenectomy after initial therapy with alpha-IFN in patients with hairy-cell leukemia (HCL): a multi-center study by the Italian Cooperative Group for HCL. Preliminary results.
Damasio EE; Federico M; Frassoldati A; Lamparelli T; Annino L; Bernasconi C; Chisesi T; Foá R; Lauria F; Pagnucco G
Eur J Haematol Suppl; 1990; 52():29-31. PubMed ID: 2279542
[TBL] [Abstract][Full Text] [Related]
17. Recombinant alpha-2 interferon for treatment of hairy cell leukemia without prior splenectomy.
Ehmann WC; Silber R
Am J Med; 1986 Jun; 80(6):1111-4. PubMed ID: 3728508
[TBL] [Abstract][Full Text] [Related]
18. The alpha 2 (r) interferon in the treatment of hairy cell leukemia: progressive report of 25 cases.
Mandelli F; Cafolla A; Annino L; Amadori S; Gentile A; Bianco P; Dianzani F
J Biol Regul Homeost Agents; 1987; 1(4):177-82. PubMed ID: 3332545
[TBL] [Abstract][Full Text] [Related]
19. Human recombinant interferon-alpha-2 in the treatment of patients with hairy cell leukemia.
Skotnicki AB; Wolska-Smolen T; Blicharski J; Zduńczyk A; Sasiadek U; Pituch-Noworolska A
Cancer Detect Prev; 1988; 12(1-6):511-22. PubMed ID: 3180143
[TBL] [Abstract][Full Text] [Related]
20. Recombinant alpha-interferon (alpha-IFN) for progressive hairy-cell leukemia (HCL): a study in previously untreated nonsplenectomized patients.
Schwarzinger I; Bettelheim P; Chott A; Herold C; Hinterberger W; Köller U; Kos M; Neumann E; Radaszkiewicz T; Lechner K
Wien Klin Wochenschr; 1988 Jan; 100(2):47-51. PubMed ID: 3348041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
